GSK plc has unveiled a plan to invest $30 billion into research, development and supply chain infrastructure across the United States. The announcement includes a fresh $1.2 billion allocation toward advanced drug manufacturing facilities, artificial intelligence and digital technologies that will support the development of new biopharmaceutical factories and laboratories in the U.S.
The $1.2 billion package covers several key projects. Among them is the construction of a new biologics flex factory in Upper Merion, Pennsylvania. The facility will focus on potential new treatments for respiratory conditions such as COPD and asthma, alongside oncology therapies targeting hematological, gynecological, lung and other solid tumors. Additional elements of the investment include advanced AI and digital technology enhancements across GSK’s five existing U.S. manufacturing sites located in Pennsylvania, North Carolina, Maryland and Montana, as well as expanded capabilities in drug manufacturing, devices and auto-injectors.
Commenting on the investment, GSK CEO Emma Walmsley said: “Alongside the many longstanding and vital shared interests that connect the U.K. and the United States, is advancing life sciences to get ahead of disease. This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both. Here in the U.K., we continue to invest in a significant manufacturing base and more than £1.5 billion in R&D every year. Today, we are committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country. $1.2 billion of today’s announcement includes construction of an additional next-gen biologics “flex” factory, powered by AI, advanced technologies and expert talent to produce transformational new respiratory and cancer medicines for American patients.”
The wider $30 billion investment will also increase U.S. clinical trial operations, with the company expecting the country to rank first worldwide for the number of studies, sites and trial participants over the next five years. In addition, GSK confirmed that the announcement brings its total new U.S. manufacturing commitments to approximately $2 billion in the past year. That figure includes the $800 million facility under construction at its Marietta, Pennsylvania site, launched in October 2024, which will double the site’s size and production capacity. These initiatives are projected to create hundreds of highly skilled roles alongside construction jobs, adding to GSK’s current U.S. workforce of around 15,000.
According to the company, GSK’s global supply chain delivered 1.7 billion packs of medicines and over 400 million vaccine doses last year, contributing to its target of positively impacting the health of 2.5 billion people worldwide by 2030.
